Class Action Lawsuit Against Biohaven Ltd.
The Law Offices of Frank R. Cruz have announced that a class action lawsuit is underway for investors of Biohaven Ltd. (BHVN) who bought shares between certain periods. If you are an investor affected by this situation, it is crucial to understand your rights and the details of this lawsuit.
Key Details of the Class Period
This class action pertains to investors who purchased Biohaven securities within the designated time frame. Those interested in participating have a specific deadline to file a motion to be considered as lead plaintiffs.
Recent Events Impacting Biohaven
On July 17, Biohaven revealed that the FDA rejected their New Drug Application for the drug known as troriluzole. This drug was intended for treating spinocerebellar ataxia, and the refusal was based on the failure of the Phase 3 trial results to meet the essential endpoints.
Impact on Stock Prices
Following the FDA's rejection news, Biohaven’s stock saw a substantial decline, dropping by 22.6%, which reflected a loss of $5.38 per share. Such declines have significantly impacted investors, raising concerns over their investments.
Further Developments
In the subsequent months, Biohaven continued to face setbacks. On March 3, 2025, the company reported disappointing results from a study regarding its treatment for bipolar mania, leading to another drop of $5.12 per share, or 13.8%.
The following press release on April 25 indicated that Biohaven had withdrawn its Marketing Authorization Application for the same drug they had earlier sought approval for. This withdrawal further led to a 15.2% decline in stock price, accumulating another loss for investors.
The Allegations Behind the Lawsuit
The lawsuit alleges that throughout the class period, the defendants made materially false statements regarding the company's business and prospects. Investors were misled about the efficacy and regulatory prospects of the treatments under review, which were later deemed to have been overstated.
How to Get Involved
If you hold Biohaven shares and are wondering how to get involved in this class action lawsuit, the Law Offices of Frank R. Cruz are available for consultations. You can reach them via phone or email to discuss potential legal options and understand the next steps.
Contact Information
To discuss your legal rights regarding this matter or to learn more about participating in the class action lawsuit, you can contact the Law Offices of Frank R. Cruz:
Address: 2121 Avenue of the Stars, Suite 800
Telephone: (310) 914-5007
Email: info@frankcruzlaw.com
Website: www.frankcruzlaw.com
Frequently Asked Questions
What should I do if I invested in Biohaven Ltd. (BHVN)?
If you purchased Biohaven shares, it's advisable to contact legal counsel to explore options for participating in the class action lawsuit.
What is the class action lawsuit about?
The lawsuit claims that Biohaven misled investors regarding the efficacy of its drugs and regulatory submissions, causing significant financial losses.
How can I recover my losses?
By participating in this class action, you may recover losses incurred from the drop in Biohaven's stock price affected by the alleged fraud.
What are the deadlines for filing?
Investors should file their lead plaintiff motions before the established deadline to ensure consideration in the lawsuit.
Where can I get more information?
For more information, reach out to the Law Offices of Frank R. Cruz via the provided contact details.
